Overall Survival with Cisplatin and 5-Fluorouracil Neoadjuvant Treatment in Patients with Esophageal Cancer: Single-Center Experience

Publisher： Karger

E-ISSN： 2296-5262|31|12|673-677

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.31, Iss.12, 2008-11, pp. : 673-677

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neoadjuvant 5 Fluorouracil-Cisplatin Chemoradiation Effect on Survival in Patients with Resectable Pancreatic Head Adenocarcinoma: A Ten-Year Single Institution Experience

By  

Oncology, Vol. 76, Iss. 6, 2009-05 ,pp. : 413-419

Karger

Access to resources Recommend Favorite

Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907)

By  

Oncology, Vol. 89, Iss. 3, 2015-04 ,pp. : 143-151

Karger

Access to resources Recommend Favorite

Prospective Phase II Study of Neoadjuvant Therapy with Cisplatin, 5-Fluorouracil, and Bevacizumab for Locally Advanced Resectable Esophageal Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 7-8, 2012-07 ,pp. : 427-431

Karger

Access to resources Recommend Favorite

The Different Impact of BRCA Mutations on the Survival of Epithelial Ovarian Cancer Patients: A Retrospective Single-Center Experience

By  

Oncology, Vol. 85, Iss. 2, 2013-08 ,pp. : 122-127

Karger

Access to resources Recommend Favorite

Feasibility of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil versus Adriamycin, Cisplatin, and 5-Fluorouracil for Resectable Advanced Esophageal Cancer

By  

Oncology, Vol. 92, Iss. 2, 2016-12 ,pp. : 101-108

Karger

Access to resources Recommend Favorite